Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death
Forms and strengths
0.5 mg scored tablet
Dosage and duration
Lactation inhibition
1 mg single dose on the first day post-partum
Lactation suppression
0.25 mg every 12 hours for 2 days
Contra-indications, adverse effects, precautions
Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis.
May cause: hypotension, valvulopathy, dizziness, headache,nausea, drowsiness, hallucinations.
Do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine(risk of vasoconstriction and hypertensive crisis), and macrolides (effectof cabergoline increased).
Pregnancy: CONTRA-INDICATED
Remarks
The use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously.
Cabergoline is not includedin the WHO list of essential medicines.
Cabergoline is a dopamine agonistalso used in the treatment of Parkinson’s disease.